LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

Search

Stevanato Group SpA

Fechado

SetorSaúde

24.97 1.55

Visão Geral

Variação de preço das ações

24h

Atual

Mín

23.61

Máximo

25.23

Indicadores-chave

By Trading Economics

Rendimento

4M

39M

Vendas

23M

280M

P/E

Médio do Setor

43.298

77.256

Rendimento de Dividendos

0.21

Margem de lucro

13.965

Funcionários

5,521

EBITDA

5.2M

62M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+15.2% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

0.21%

2.33%

Próximos Ganhos

6 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-243M

6.7B

Abertura anterior

23.42

Fecho anterior

24.97

Sentimento de Notícias

By Acuity

50%

50%

165 / 374 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Stevanato Group SpA Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de nov. de 2025, 23:51 UTC

Ganhos

CoreCivic Cuts Fiscal Year Guidance Amid Efforts to Launch New Detention Facilities

5 de nov. de 2025, 23:10 UTC

Ganhos

DBS Third Quarter Net Dips 2.0%

5 de nov. de 2025, 22:55 UTC

Ganhos

Arm Holdings 2Q Profit Climbs on Record Demand

5 de nov. de 2025, 22:23 UTC

Ganhos

NAB's Annual Profit Falls 2.9% Amid Higher Costs, Credit Impairments -- Update

5 de nov. de 2025, 23:52 UTC

Ganhos

United Overseas Bank 3Q Net Interest Income S$2.265B Vs. $2.46B >U11.SG

5 de nov. de 2025, 23:49 UTC

Ganhos

United Overseas Bank 3Q Total Income S$3.40B Vs. S$3.83B >U11.SG

5 de nov. de 2025, 23:49 UTC

Ganhos

United Overseas Bank 3Q Net S$443M Vs. Net S$1.61B >U11.SG

5 de nov. de 2025, 23:45 UTC

Conversa de Mercado

Nikkei May Rise on Weaker Yen, U.S. Tech Rebound -- Market Talk

5 de nov. de 2025, 23:42 UTC

Conversa de Mercado

Gold Edges Lower Amid Reduced Odds of Fed Rate-Cut -- Market Talk

5 de nov. de 2025, 23:12 UTC

Ganhos

Nutrien 3Q Adj EPS 97c >NTR.T

5 de nov. de 2025, 23:11 UTC

Ganhos

Nutrien: Initiating Review of Strategic Alternatives for Phosphate Business >NTR.T

5 de nov. de 2025, 23:10 UTC

Ganhos

Nutrien 3Q Sales $6.01B >NTR.T

5 de nov. de 2025, 23:10 UTC

Conversa de Mercado
Ganhos

AppLovin Says Conversion Rate Is Biggest Growth Lever -- Market Talk

5 de nov. de 2025, 23:10 UTC

Ganhos

Nutrien 3Q EPS 96c >NTR.T

5 de nov. de 2025, 23:04 UTC

Ganhos

Qualcomm Stock Slides After Earnings Beat -- Barrons.com

5 de nov. de 2025, 23:03 UTC

Conversa de Mercado

Macklem: Canada's Regulatory Overlap Turns Off Foreign Investors -- Market Talk

5 de nov. de 2025, 22:55 UTC

Conversa de Mercado

Macklem Says Inflation and Productivity Are Intertwined -- Market Talk

5 de nov. de 2025, 22:55 UTC

Ganhos

AppLovin Reports Strong Earnings. The Stock Is Up. -- Barrons.com

5 de nov. de 2025, 22:51 UTC

Ganhos

DBS 3Q Total Income S$5.93B, Up 3% on Year >D05.SG

5 de nov. de 2025, 22:50 UTC

Ganhos

DBS 3Q Net S$2.95B, Down 2.0% on Year >D05.SG

5 de nov. de 2025, 22:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Pfizer Preps Improved Offer in Metsera Bidding War -- Update

5 de nov. de 2025, 22:43 UTC

Conversa de Mercado
Ganhos

NAB's Flat Dividend Disappoints Bears at Jarden -- Market Talk

5 de nov. de 2025, 22:36 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

5 de nov. de 2025, 22:36 UTC

Conversa de Mercado

Macklem Warns Structural Adjustment Means Slow Canadian Growth -- Market Talk

5 de nov. de 2025, 22:20 UTC

Conversa de Mercado

Bank of Canada Says Budget Plan Identifies Economy's Biggest Weakness -- Market Talk

5 de nov. de 2025, 22:12 UTC

Aquisições, Fusões, Aquisições de Empresas

Pfizer: Will Take Action to Preserve Rights Under Previously-Signed Agreement >PFE

5 de nov. de 2025, 22:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Pfizer: Confident in Merits of Claims, Belief Metsera Has Acted in Breach of Contractual Obligations >PFE

5 de nov. de 2025, 22:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Pfizer Responds to Delaware Chancery Court Ruling

5 de nov. de 2025, 22:01 UTC

Ganhos

Great-West Lifeco 3Q Net C$1.16B >GWO.T

5 de nov. de 2025, 22:01 UTC

Ganhos

Great-West Lifeco 3Q Adj EPS C$1.33 >GWO.T

Comparação entre Pares

Variação de preço

Stevanato Group SpA Previsão

Preço-alvo

By TipRanks

15.2% parte superior

Previsão para 12 meses

Média 28.5 USD  15.2%

Máximo 32 USD

Mínimo 24 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Stevanato Group SpA - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

4 ratings

2

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

21.56 / 22.61Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Weak Bearish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

165 / 374 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Stevanato Group SpA

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
help-icon Live chat